Home Pharmacy and Verification
Pharmacy and Verification
Eight checks you can complete before you pay, none of which require clinical training.
Compounded tirzepatide is prepared by a licensed pharmacy for an individual patient with a valid prescription. It is not FDA-approved and is not reviewed by FDA for safety, effectiveness or quality before marketing, which makes the identity and standards of the dispensing pharmacy the thing you are relying on.
The checks below are all completable from public records and from questions any legitimate program will answer in writing.
Verification
How to Verify a Compounding Pharmacy
Five checks, none of which require you to be a pharmacist.
503A vs 503B Compounding
One dispenses for a named patient. The other manufactures batches under FDA registration.
Tirzepatide API Sourcing
The active ingredient has a supply chain, and not all of it is legitimate.
Sterility and Potency Testing
An injectable that was never tested for sterility is an injectable you are testing yourself.
Tirzepatide Cold Chain
The medication is only as good as the coldest and warmest points of its journey.
Beyond-Use Dating
It is not an expiry date, and it usually arrives before the vial is empty.
State Pharmacy Licensing
Both the prescriber and the pharmacy need to be licensed where you are.
Compounding Pharmacy Red Flags
Any one of these is enough to walk away from a program.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.